source
- Addex spinout Neurosterix raises $105M series B to fund phase 2 schizophrenia trialAddex Therapeutics’ neuropsychiatric-focused spinout has raised $105 million in series B funds to bankroll a planned phase 2 study of its schizophrenia treatment.Fierce Biotech · 6h ago↗ source
- Pfizer taps Blackstone for up to $1.5B to pave path to GLP-1's obesity launchPfizer has secured up to $1.5 billion from Blackstone Life Sciences to fund development of its monthly GLP-1 receptor agonist.Fierce Biotech · 6h ago↗ source
- Abbott nabs FDA approval, CE Mark for implantable cardioverter-defibrillator leadAbbott has received both FDA and CE Mark approval for its UltiSynq defibrillation lead tech, which is designed to deliver both conduction system pacing and defibrillation therapy.